ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

Study summary

The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those who are 65 years and older. They will also analyze whether these efforts lower the cost of care compared to standard of care.

Ask AI to explain this study

Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedAccess to Cue Health COVID-19 Remote testing and treatment for COVID-19

The study team can explain what participation involves.

Who it may be forImmunodeficiency · Immunosuppression

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 8, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Scripps Translational Science Institute

Study sponsor

Study overview

What this study is about

Purpose: Other
Study type: Interventional
Phase: Not applicable
Sponsor: Scripps Translational Science Institute
Interventions being studied: Other: Access to Cue Health COVID-19 Remote testing and treatment for COVID-19

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Living in the United States
18 years or older
Can read and understand English
Use of smartphone with bluetooth, a camera and a compatible operating system (Android OS 9.0 or higher, Apple iOS 13.0 or higher)
Vaccinated against COVID-19 (completed at least the initial course, e.g. at least 2 doses of -Moderna or Pfizer, one dose of J\&J)
Willing and able to participate in study interventions including: 1. Use of smartphone, including camera and bluetooth 2. Upload verification of diagnosis, if needed 3. Completing Surveys 4. Use of Cue Health App 5. Use of MyDataHelps Web or App
Immunocompromised due to disease or therapy, including: 1. Symptomatic HIV 2. Graft versus host disease 3. Immunoglobulin deficiency/Immunodeficiency 4. Immunosuppressive therapy 5. Leukemia 6. Lymphoma (Hodgkin or non-Hodgkin) 7. Metastatic Cancer 8. Multiple Myeloma 9. Solid organ malignancy 10. Transplant, hematopoietic stem cell 11. Transplant, solid organ
Age 1. 65 years and older Option if under 65 to share claims data as a member of one of the following insurance providers: 1. Anthem BlueCross and BlueShield 2. Anthem BlueCross 3. Empire BlueCross BlueShield 4. Empire BlueCross 5. Wellpoint 6. Carelon 7. Unicare 8. Simply Healthcare Plans 9. National Government Services, Inc. 10. MMM 11. Health Sun 12. HealthLink 13. Amerigroup 14. Medicare 15. Medicaid 16. Or another partner that can provide claims data on participant's behalf

Reasons someone may not be able to joinExclusion criteria

Unable to meet inclusion criteria

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Scripps ResearchLa Jolla, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 8, 2025. Always confirm current availability with the study team.

View original record ↗